Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).Giovanni Scambia, Domenica Lorusso, Giorgio Valabrega et al.|Journal of Clinical Oncology|2022Cited by 6